JP EQUITY · SINGLE-STOCK DEEP DIVE · 東亞合成

도아고세이 — 덩치도 이익도 기간화학품이 지킨다, 돈을 넣은 곳에서 수익률이 무너졌다Toagosei — commodity chemicals hold up both size and profit; returns collapsed where the money went in東亞合成 — 規模も利益も基幹化学品が支え、資金を投じたところで収益率が崩れた

한 회사 안에 전해(가성소다·염소)와 아크릴 모노머라는 범용 화학, 폴리머·올리고머라는 중간재, 아론알파로 대표되는 접착제와 고기능 재료라는 스페셜티가 같이 있다. EDINET 공시 14년치를 부문별로 이어 붙여 어느 부문이 이익을 내고 어디에 자산이 쌓였는지, 아크릴산 가격이 어디까지 닿는지 가르고(①~⑨), 모든 일본 종목에 같은 틀로 거는 재무 점검(⑩~)으로 손익 엔진·현금·자본 배분·밸류에이션을 잰다. 방향은 단정하지 않는다.One company houses commodity chemicals — electrolysis (caustic soda, chlorine) and acrylic monomers — intermediates in polymers and oligomers, and specialties in adhesives, typified by Aron Alpha, and high-performance materials. Linking 14 years of EDINET filings by segment, we separate which segments earn the profit, where assets have piled up and how far acrylic acid prices reach (①~⑨), then measure the profit engine, cash, capital allocation and valuation with the financial check applied to every Japanese stock in the same frame (⑩~). No view on direction is taken.1つの会社の中に、電解(苛性ソーダ・塩素)とアクリルモノマーという汎用化学、ポリマー・オリゴマーという中間材、 アロンアルフアに代表される接着剤と高機能材料というスペシャリティが同居している。EDINETの開示14年分をセグメント別につなぎ、 どのセグメントが利益を出し、どこに資産が積み上がったか、アクリル酸価格がどこまで効くかを分け(①~⑨)、 すべての日本株に同じ枠組みで掛ける財務点検(⑩~)で損益エンジン・現金・資本配分・バリュエーションを測る。方向は断定しない。

부문 구분이 다섯 번 바뀌었다(2016·2017·2022·2023·2025). 2017년 전면 개편 전후는 잇지 않고, 2017년부터의 다섯 부문만 시계열로 쓴다. 2022년 접착재료의 개발제품 일부가 고기능 재료로, 2023년 지속가능 관련 사업이 기간화학품에서 기타로 옮겨졌다. 일본은 2024년 4월부터 분기보고서가 폐지돼 그 뒤는 반기뿐이다. 주가·P/B·배당수익률은 공시된 EPS × PER 로 역산한 가공값이다. 아크릴산 가격은 관세청 한국 수출 단가로, 도아고세이의 판매가가 아니다. FY = 1~12월 · 일본기준(J-GAAP).The segment structure changed five times (2016 · 2017 · 2022 · 2023 · 2025). The series is not linked across the 2017 overhaul, and only the five segments from 2017 onwards are used as time series. In 2022 some development products moved from adhesives to high-performance materials, and in 2023 sustainability-related businesses moved from commodity chemicals to other. Japan abolished quarterly securities reports from April 2024, so after that there are only half-year figures. Share prices, P/B and dividend yields are derived values back-calculated from disclosed EPS × P/E. Acrylic acid prices are Korean export unit values from the Korea Customs Service, not Toagosei’s selling prices. FY = January–December · Japan GAAP (J-GAAP).セグメント区分は5回変わった(2016・2017・2022・2023・2025)。2017年の全面改編の前後はつながず、2017年以降の5セグメントだけを時系列に使う。 2022年に接着材料の開発製品の一部が高機能材料へ、2023年にサステナビリティ関連事業が基幹化学品からその他へ移った。 日本では2024年4月から四半期報告書が廃止され、それ以降は半期のみ。株価・P/B・配当利回りは開示されたEPS × PERから逆算した加工値だ。 アクリル酸価格は韓国関税庁の韓国輸出単価で、東亞合成の販売価格ではない。FY = 1~12月 · 日本基準(J-GAAP)。
매출 FY2025Revenue FY2025売上高 FY20251,623억엔1,623 JPY 100mn1,623億円FY2012 1,482억엔FY2012 1,482 JPY 100mnFY2012 1,482億円
영업이익률Operating margin営業利益率8.7%ROE 6.0%
기간화학품 이익 비중Commodity chemicals’ share of profit基幹化学品の利益比重55%FY2016 29% → FY2025
접착재료 영업이익률Adhesives operating margin接着材料の営業利益率2.4%FY2016 23.5%
ROIC(영업 투하자본)ROIC (operating invested capital)ROIC(営業投下資本)6.6%고점 FY2017 15.1%Peak FY2017 15.1%ピーク FY2017 15.1%
안전마진Margin of safety安全余裕率24.1%FY2015 27.9%
P/B (가공)P/B (derived)P/B(加工値)0.82배0.82x0.82倍배당수익률 3.97%Dividend yield 3.97%配当利回り3.97%
총환원율 FY2025Total payout ratio FY2025総還元性向 FY2025110%배당성향 55.5%Payout ratio 55.5%配当性向55.5%

한눈에 — 네 가지 관측At a glance — four observationsひと目で — 4つの観測

아래 절의 숫자를 모은 것Figures collected from the sections below下の節の数字をまとめたもの · Data as of 2026-09-30 · Created 2026-11-01
이익의 계단 없음No step-up in profit利益の階段なし
153 → 151
경상이익(억엔) FY2012 → FY2025. 손익분기 매출은 1,009 → 1,232억엔으로 올라 안전마진이 27.9% → 24.1% 로 얇아졌다(⑫).Ordinary profit (JPY 100mn) FY2012 → FY2025. Break-even revenue rose from 1,009 to 1,232 JPY 100mn, thinning the margin of safety from 27.9% to 24.1% (⑫).経常利益(億円)FY2012 → FY2025。損益分岐点売上高は1,009 → 1,232億円に上がり、安全余裕率は27.9% → 24.1%に薄くなった(⑫)。
버티는 건 기간화학품Commodity chemicals are what holds up持ちこたえているのは基幹化学品
29% → 55%
부문 이익 중 기간화학품 몫. 좋아져서가 아니라 나머지가 내려와서다. 마진 개선의 절반은 감가상각 비율 하락(⑨).Commodity chemicals’ share of segment profit. Not because it improved, but because the rest came down. Half of the margin improvement is the fall in the depreciation ratio (⑨).セグメント利益に占める基幹化学品の分。良くなったからではなく、残りが下がったからだ。マージン改善の半分は減価償却比率の低下(⑨)。
투자 → 결과 끊김Investment → results disconnect投資 → 成果の断絶
1,173억엔1,173 JPY 100mn1,173億円
스페셜티 3부문 설비투자 + 전사 연구개발 FY2016~FY2025. 같은 기간 3부문 이익 92 → 45억엔(⑧). 전사 ROIC 8.5% → 6.6%(⑯).Capex in the three specialty segments + company-wide R&D, FY2016~FY2025. Profit of the three segments over the same period 92 → 45 JPY 100mn (⑧). Company-wide ROIC 8.5% → 6.6% (⑯).スペシャリティ3セグメントの設備投資 + 全社研究開発 FY2016~FY2025。同期間の3セグメント利益92 → 45億円(⑧)。全社ROIC 8.5% → 6.6%(⑯)。
주가는 장부에 묶였다The share price is anchored to book株価は簿価に縛られた
P/B 0.66~1.03
ROE 가 변해도 P/B 가 거의 안 움직인다 — 그해 이익 기준 β 0.02(1 = 이익을 따라감, 0 = 장부에 묶임). 3년 평균 이익 기준으로는 β 0.57(㉒).P/B barely moves as ROE changes — β on same-year earnings 0.02 (1 = tracks earnings, 0 = anchored to book). On 3-year average earnings, β 0.57 (㉒).ROEが変わってもP/Bはほとんど動かない — その年の利益ベースでβ 0.02(1 = 利益に連動、0 = 簿価に縛られる)。3年平均利益ベースではβ 0.57(㉒)。

① 10년 넘게 이익은 제자리① Profit has gone nowhere for over 10 years① 10年以上、利益は横ばい

Data as of 2026-09-30 · Created 2026-11-01

경상이익은 FY2012 153억엔, FY2025 151억엔이다. 그 사이 매출은 1,482억엔에서 1,623억엔으로 움직였지만 이익의 계단은 생기지 않았다. 영업이익률은 연결 손익계산서가 있는 FY2015 이후로 그린다.Ordinary profit was 153 JPY 100mn in FY2012 and 151 JPY 100mn in FY2025. Revenue moved from 1,482 to 1,623 JPY 100mn in between, but no step-up in profit emerged. Operating margin is plotted from FY2015, when consolidated income statements are available.経常利益はFY2012 153億円、FY2025 151億円だ。 その間に売上高は1,482億円から1,623億円へ動いたが、利益の階段は生まれなかった。 営業利益率は連結損益計算書があるFY2015以降を描く。

경상이익 · 억엔Ordinary profit · JPY 100mn経常利益 · 億円 · Data as of 2026-09-30 · Created 2026-11-01
영업이익률 · 경상이익률 · %Operating margin · ordinary margin · %営業利益率 · 経常利益率 · % · Data as of 2026-09-30 · Created 2026-11-01
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 경상이익은 有報 5년 표의 연결 값(앞 연도는 뒤 보고서가 소급한 값) · 영업이익률은 연결 손익계산서가 있는 해부터.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Ordinary profit is the consolidated figure from the 5-year table in the annual securities report (earlier years use values restated retroactively by later reports) · operating margin starts from the years with a consolidated income statement.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 経常利益は有報5年表の連結の値(前の年度は後の報告書が遡及した値)· 営業利益率は連結損益計算書がある年から。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

② 이익은 기간화학품이 낸다② Commodity chemicals generate the profit② 利益を出すのは基幹化学品

Data as of 2026-09-30 · Created 2026-11-01

FY2025 부문 이익의 55%가 기간화학품이다(FY2016 29%). 기간화학품은 전해 제품(가성소다·가성칼리·차아염소산소다)·황산·공업용 가스와 아크릴 모노머(아크릴산·에스테르)를 묶은 부문이다 — 말하자면 외형도, 지금의 이익도 범용 화학이 만든다.In FY2025, 55% of segment profit came from commodity chemicals (FY2016 29%). Commodity chemicals bundles electrolysis products (caustic soda, caustic potash, sodium hypochlorite), sulphuric acid, industrial gases and acrylic monomers (acrylic acid, esters) — in other words, both the top line and today’s profit are made by commodity chemicals.FY2025のセグメント利益の55%が基幹化学品だ(FY2016 29%)。 基幹化学品は電解製品(苛性ソーダ・苛性カリ・次亜塩素酸ソーダ)・硫酸・工業用ガスとアクリルモノマー(アクリル酸・エステル)を束ねたセグメントだ — いわば売上規模も今の利益も汎用化学がつくる。

부문 영업이익 · 억엔Segment operating profit · JPY 100mnセグメント営業利益 · 億円 · Data as of 2026-09-30 · Created 2026-11-01
부문 (FY2025)Segment (FY2025)セグメント(FY2025)매출(억엔)Revenue (JPY 100mn)売上高(億円)영업이익(억엔)Operating profit (JPY 100mn)営業利益(億円)이익률Margin利益率이익 비중Profit share利益比重자산 수익률Return on assets資産利益率투자 ÷ 감가상각Capex ÷ depreciation投資 ÷ 減価償却費
기간화학품Commodity chemicals基幹化学品基幹化学品事業 750 88 11.7% 55% 10.7% 1.93
폴리머·올리고머Polymers & oligomersポリマー・オリゴマーポリマー・オリゴマー事業 377 30 8.0% 19% 5.9% 4.13
접착재료Adhesives接着材料接着材料事業 137 3 2.4% 2% 1.4% 4.07
고기능 재료High-performance materials高機能材料高機能材料事業 107 12 11.0% 7% 5.3% 3.30
수지가공 제품Plastic processed products樹脂加工製品樹脂加工製品事業 290 28 9.5% 17% 6.1% 0.70
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 부문 구분이 여러 번 바뀌었다 — 2017년 개편 전후는 잇지 않았고, 이후 이관은 그때 기준 그대로다(소급하지 않음). 부문 이익은 조정 전 합계.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: The segment structure changed several times — the series is not linked across the 2017 overhaul, and later transfers are kept on the basis of their time (not restated). Segment profit is the total before adjustments.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: セグメント区分は何度も変わった — 2017年の改編の前後はつないでおらず、その後の移管は当時の基準のまま(遡及しない)。セグメント利益は調整前の合計。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

③ 돈을 넣은 부문에서 수익률이 무너졌다③ Returns collapsed in the segments where money went in③ 資金を投じたセグメントで収益率が崩れた

Data as of 2026-09-30 · Created 2026-11-01

부문 자산 수익률(영업이익 ÷ 부문 자산)로 보면, 고기능 재료는 FY 고점 무렵 35.4%에서 FY2025 5.3%로 내려왔다. 같은 기간 고기능·폴리머·접착 부문은 감가상각의 몇 배를 다시 투자해 자산이 커졌는데, 이익은 따라오지 않았다. 반대로 기간화학품은 오랫동안 투자가 감가상각에 못 미쳤다 — 낡은 설비를 돌려 이익을 낸 구조다.Measured by segment return on assets (operating profit ÷ segment assets), high-performance materials fell from 35.4% around its FY peak to 5.3% in FY2025. Over the same period the high-performance, polymer and adhesive segments reinvested several times their depreciation and their assets grew, but profit did not follow. Commodity chemicals, by contrast, invested less than its depreciation for a long time — a structure that earned profit by running old plants.セグメント資産利益率(営業利益 ÷ セグメント資産)で見ると、高機能材料はFYのピーク付近の35.4%からFY2025には5.3%に下がった。 同じ期間、高機能・ポリマー・接着の各セグメントは減価償却費の数倍を再投資して資産が大きくなったが、利益はついてこなかった。 反対に基幹化学品は長い間、投資が減価償却費に届かなかった — 古い設備を回して利益を出した構造だ。

부문 자산 수익률 · %Segment return on assets · %セグメント資産利益率 · % · Data as of 2026-09-30 · Created 2026-11-01
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 부문 자산은 부문별 공시 자산(전사 공통 자산 제외) · 2022년 이관 전후로 자산 기준이 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Segment assets are the assets disclosed by segment (excluding company-wide corporate assets) · the asset basis differs before and after the 2022 transfer.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: セグメント資産はセグメント別に開示された資産(全社共通資産を除く)· 2022年の移管の前後で資産の基準が異なる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

④ 접착재료 — 가장 눈에 띄는 몰락④ Adhesives — the most striking decline④ 接着材料 — 最も目立つ凋落

Data as of 2026-09-30 · Created 2026-11-01

접착재료 영업이익률은 FY2016 23.5%에서 FY2022 -2.3%까지 떨어졌고 FY2025 2.4%다. 2022년의 구분 변경(개발제품 일부 이관) 이전인 2019년부터 이미 내려가고 있었다. 일본산 아크릴산의 상대가격(프로필렌 대비)과는 계절·추세를 뺀 전년 동기 대비로도 상관이 -0.73이다 — 원료가 압박일 수 있지만, 일본발 수입 물량이 작아 가설로만 둔다.The adhesives operating margin fell from 23.5% in FY2016 to -2.3% in FY2022 and is 2.4% in FY2025. It was already declining from 2019, before the 2022 reclassification (transfer of some development products). Its correlation with the relative price of Japanese acrylic acid (vs propylene) is -0.73 even on a year-on-year basis that strips out seasonality and trend — raw-material costs may be the pressure, but import volumes from Japan are small, so this stays a hypothesis.接着材料の営業利益率はFY2016の23.5%からFY2022の-2.3%まで下がり、FY2025は2.4%だ。 2022年の区分変更(開発製品の一部移管)より前の2019年から、すでに下がっていた。 日本産アクリル酸の相対価格(プロピレン比)とは、季節・トレンドを除いた前年同期比でも相関が-0.73だ — 原料価格が圧迫要因かもしれないが、日本からの輸入数量が小さいため仮説にとどめる。

부문 영업이익률 · %Segment operating margin · %セグメント営業利益率 · % · Data as of 2026-09-30 · Created 2026-11-01
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 2024년 하반기부터는 반기 값 · 2022년 접착재료 개발제품 일부가 고기능 재료로 옮겨 그 전후 비교가 끊긴다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: From the second half of 2024 the values are half-yearly · in 2022 some development products moved from adhesives to high-performance materials, breaking comparability across that point.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 2024年下期からは半期の値 · 2022年に接着材料の開発製品の一部が高機能材料へ移り、その前後の比較が途切れる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑤ 아크릴산은 가격으로 닿고, 스프레드로는 안 닿는다⑤ Acrylic acid reaches through price, not through the spread⑤ アクリル酸は価格では効き、スプレッドでは効かない

Data as of 2026-09-30 · Created 2026-11-01

기간화학품 분기 마진은 아크릴산 가격과 같이 움직인다 — 전년 동기 대비 변화끼리의 상관 0.54. 원료(프로필렌)를 뺀 스프레드와는 수준 상관이 0.10로 약하고, 스프레드로 만든 함수는 표본 밖에서 직전 4분기 평균보다 낫지 않았다(2.21%p vs 2.13%p). 부문에 나고야 지역 내수용 전해 제품이 함께 들어 있고, 아크릴 단가가 아시아 수출 시세라는 점이 함께 걸린다.The quarterly margin of commodity chemicals moves with the acrylic acid price — correlation of year-on-year changes 0.54. With the spread net of the raw material (propylene), the level correlation is weak at 0.10, and a function built on the spread did no better out of sample than the trailing four-quarter average (2.21pp vs 2.13pp). Two further caveats: the segment also contains electrolysis products for domestic demand in the Nagoya area, and the acrylic unit values are Asian export prices.基幹化学品の四半期マージンはアクリル酸の価格と一緒に動く — 前年同期比の変化同士の相関0.54。 原料(プロピレン)を差し引いたスプレッドとは水準の相関が0.10と弱く、 スプレッドで作った関数は標本外で直前4四半期平均より良くなかった(2.21%pt vs 2.13%pt)。 セグメントに名古屋地区の内需向け電解製品が一緒に入っていること、アクリルの単価がアジアの輸出相場であることも併せて関わる。

기간화학품 영업이익률 · %Commodity chemicals operating margin · %基幹化学品の営業利益率 · % · Data as of 2026-09-30 · Created 2026-11-01
아크릴산 · 프로필렌 한국 수출 단가 · US$/tAcrylic acid · propylene Korean export unit values · US$/tアクリル酸・プロピレンの韓国輸出単価 · US$/t · Data as of 2026-09-30 · Created 2026-11-01
부문Segmentセグメント비교 대상Compared with比較対象수준Level水準분기 차분QoQ difference前期差전년 동기 차분YoY difference前年同期差분기 수Quarters四半期数
기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 아크릴산 가격(한국 수출)Acrylic acid price (Korean exports)アクリル酸価格(韓国輸出) 0.38 0.10 0.54 34
기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 아크릴산 스프레드 비율(한국 수출)Acrylic acid spread ratio (Korean exports)アクリル酸スプレッド比率(韓国輸出) 0.10 -0.19 0.35 34
기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 아크릴산 가격(일본발 수입)Acrylic acid price (imports from Japan)アクリル酸価格(日本からの輸入) 0.33 0.37 0.24 34
기간화학품(전해 + 아크릴 모노머)Commodity chemicals (electrolysis + acrylic monomers)基幹化学品事業 스프레드 비율(일본발 아크릴산)Spread ratio (acrylic acid from Japan)スプレッド比率(日本発アクリル酸) 0.01 0.15 -0.32 34
폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 아크릴산 가격(한국 수출)Acrylic acid price (Korean exports)アクリル酸価格(韓国輸出) -0.05 -0.09 0.12 34
폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 아크릴산 스프레드 비율(한국 수출)Acrylic acid spread ratio (Korean exports)アクリル酸スプレッド比率(韓国輸出) 0.19 0.10 0.16 34
폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 아크릴산 가격(일본발 수입)Acrylic acid price (imports from Japan)アクリル酸価格(日本からの輸入) -0.31 -0.21 -0.07 34
폴리머·올리고머Polymers & oligomersポリマー・オリゴマー事業 스프레드 비율(일본발 아크릴산)Spread ratio (acrylic acid from Japan)スプレッド比率(日本発アクリル酸) -0.30 -0.04 -0.16 34
접착재료(아론알파 등)Adhesives接着材料事業 아크릴산 가격(한국 수출)Acrylic acid price (Korean exports)アクリル酸価格(韓国輸出) -0.03 0.03 0.10 34
접착재료(아론알파 등)Adhesives接着材料事業 아크릴산 스프레드 비율(한국 수출)Acrylic acid spread ratio (Korean exports)アクリル酸スプレッド比率(韓国輸出) 0.11 -0.23 -0.11 34
접착재료(아론알파 등)Adhesives接着材料事業 아크릴산 가격(일본발 수입)Acrylic acid price (imports from Japan)アクリル酸価格(日本からの輸入) -0.56 0.16 -0.28 34
접착재료(아론알파 등)Adhesives接着材料事業 스프레드 비율(일본발 아크릴산)Spread ratio (acrylic acid from Japan)スプレッド比率(日本発アクリル酸) -0.76 -0.15 -0.73 34
상관은 동행이지 인과가 아니다. 추세가 겹친 우연을 거르려고 수준·분기 차분·전년 동기 차분을 함께 싣는다.Correlation is co-movement, not causation. Level, quarter-on-quarter and year-on-year differences are shown together to filter out coincidences from overlapping trends.相関は連動であって因果ではない。トレンドが重なった偶然を除くため、水準・前期差・前年同期差を併せて載せる。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 아크릴산·프로필렌은 관세청 한국 수출 단가 — 도아고세이의 판매가·구매가가 아니다. 기간화학품엔 전해 제품이 함께 들어 있다. 상관은 동행이지 인과가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: Acrylic acid and propylene are Korean export unit values from the Korea Customs Service — not Toagosei’s selling or purchase prices. Commodity chemicals also includes electrolysis products. Correlation is co-movement, not causation.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: アクリル酸・プロピレンは韓国関税庁の韓国輸出単価 — 東亞合成の販売価格・購入価格ではない。基幹化学品には電解製品も含まれる。相関は連動であって因果ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑥ 2012년 日本触媒 폭발 — 일본은 한국 아크릴산을 사 갔다⑥ The 2012 Nippon Shokubai explosion — Japan bought Korean acrylic acid⑥ 2012年の日本触媒の爆発 — 日本は韓国のアクリル酸を買っていった

Data as of 2026-09-30 · Created 2026-11-01

日本触媒 姫路 공장 아크릴산 탱크 폭발(2012년 9월 29일) 뒤, 한국의 대일 아크릴산 수출은 월 0.2kt(2012년 7~9월)에서 2.8kt(2012년 10월~2013년 3월)로 늘었다. 아시아 수출 가격은 오르지 않았다 — 일본 국내 수급만 빠듯해졌다는 뜻이다. 도아고세이 연결 경상이익은 FY2012 153억엔, FY2013 153억엔, FY2014 129억엔이었다 (부문 숫자는 EDINET 목록 API 의 10년 창 밖이라 없다).After the acrylic acid tank explosion at Nippon Shokubai’s Himeji plant (29 September 2012), Korea’s acrylic acid exports to Japan rose from 0.2 kt a month (July–September 2012) to 2.8 kt (October 2012–March 2013). Asian export prices did not rise — meaning only Japan’s domestic supply and demand tightened. Toagosei’s consolidated ordinary profit was 153 JPY 100mn in FY2012, 153 JPY 100mn in FY2013 and 129 JPY 100mn in FY2014 (segment figures are unavailable because they fall outside the 10-year window of the EDINET list API).日本触媒姫路製造所のアクリル酸タンク爆発(2012年9月29日)の後、韓国の対日アクリル酸輸出は 月0.2kt(2012年7~9月)から2.8kt(2012年10月~2013年3月)に増えた。 アジアの輸出価格は上がらなかった — 日本国内の需給だけが逼迫したという意味だ。 東亞合成の連結経常利益はFY2012 153億円、FY2013 153億円、FY2014 129億円だった (セグメントの数字はEDINET書類一覧APIの10年の窓の外のため、ない)。

한국의 대일 아크릴산 수출 · 일본발 수입 · kt/월Korea’s acrylic acid exports to Japan · imports from Japan · kt/month韓国の対日アクリル酸輸出 · 日本からの輸入 · kt/月 · Data as of 2026-09-30 · Created 2026-11-01
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 한국 통관 통계만 — 일본 안 생산·재고·가격은 관측하지 않았다. 그 무렵 도아고세이 부문 숫자는 EDINET 목록 범위 밖이라 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: Korean customs statistics only — production, inventories and prices within Japan were not observed. Toagosei’s segment figures for that time fall outside the range of the EDINET list, so they are unavailable.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 韓国の通関統計のみ — 日本国内の生産・在庫・価格は観測していない。当時の東亞合成のセグメントの数字はEDINET書類一覧の範囲外のため、ない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑦ 배당은 세 배, 주가는 장부가 아래⑦ Dividends tripled; the share price sits below book⑦ 配当は3倍、株価は簿価割れ

Data as of 2026-09-30 · Created 2026-11-01

주당배당금(현 주식 기준)은 FY2012 20엔에서 FY2025 65엔이 됐고, FY2025 총환원율은 110%다. P/B(가공)는 FY2025 0.82배. 정책보유주식(상장)은 FY2019 이후 줄고 있지만, 연결 순자산 대비 장부가는 FY2025 14.3%로 회사가 밝힌 '10% 정도' 목표보다 높다.Dividend per share (current share basis) went from JPY 20 in FY2012 to JPY 65 in FY2025, and the total payout ratio in FY2025 is 110%. P/B (derived) is 0.82x in FY2025. Cross-shareholdings (listed) have been falling since FY2019, but their book value relative to consolidated net assets is 14.3% in FY2025, above the company’s stated target of ‘around 10%’.1株当たり配当金(現在の株式ベース)はFY2012の20円からFY2025には65円になり、 FY2025の総還元性向は110%だ。P/B(加工値)はFY2025で0.82倍。 政策保有株式(上場)はFY2019以降減っているが、連結純資産に対する簿価はFY2025で14.3%と、会社が示した「10%程度」の目標より高い。

주당배당금(현 주식 기준) · 엔Dividend per share (current share basis) · JPY1株当たり配当金(現在の株式ベース)· 円 · Data as of 2026-09-30 · Created 2026-11-01
P/B(가공) · 배P/B (derived) · xP/B(加工値)· 倍 · Data as of 2026-09-30 · Created 2026-11-01
FY상장 정책보유 종목 수Listed cross-shareholdings (number of stocks)上場政策保有銘柄数상장 장부가(억엔)Listed book value (JPY 100mn)上場分の簿価(億円)연결 순자산 대비vs consolidated net assets連結純資産比
2016 — 241 (상장·비상장 합산)241 (listed and unlisted combined)241(上場・非上場の合計) 13.9%
2017 — 322 (상장·비상장 합산)322 (listed and unlisted combined)322(上場・非上場の合計) 17.2%
2018 — 254 (상장·비상장 합산)254 (listed and unlisted combined)254(上場・非上場の合計) 13.3%
2019 75 256 13.2%
2020 70 236 12.3%
2021 52 250 12.6%
2022 45 242 12.0%
2023 38 282 13.7%
2024 37 287 14.0%
2025 34 300 14.3%
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 주당배당금은 2015년 주식병합을 반영한 현 주식 기준 · P/B 는 EPS × PER 로 역산한 가공 주가 기준 — 시장 주가 원천이 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Dividend per share is on the current share basis, reflecting the 2015 share consolidation · P/B is based on derived prices back-calculated as EPS × P/E — not a market price source.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 1株当たり配当金は2015年の株式併合を反映した現在の株式ベース · P/BはEPS × PERで逆算した加工株価ベース — 市場の株価データではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑧ 투자는 늘었는데 매출·이익으로 이어지지 않는다⑧ Investment rose but did not translate into revenue and profit⑧ 投資は増えたが売上高・利益につながらない

Data as of 2026-09-30 · Created 2026-11-01

스페셜티 3부문(접착재료·고기능 재료·폴리머·올리고머)에 FY2016~FY2025 동안 설비투자 717억엔(감가상각 311억엔)이 들어갔고, 전사 연구개발비는 같은 기간 456억엔이다. 연구개발비는 FY2016 37억엔에서 FY2025 67억엔이 됐다. 그 사이 3부문 매출은 472억엔에서 621억엔으로 늘었지만, 영업이익은 92억엔에서 45억엔으로 줄었다 — 9년 중 6년이 전년보다 낮았다. 늘어난 매출이 늘어난 감가상각·비용을 감당하지 못하는 구조가 길게 이어진다. 연구개발비는 부문별로 공시되지 않아 전사 합계를 함께 놓았다. 최근 2년의 대규모 투자는 아직 가동 전일 수 있다.The three specialty segments (adhesives, high-performance materials, polymers & oligomers) received 717 JPY 100mn of capex over FY2016~FY2025 (depreciation 311 JPY 100mn), and company-wide R&D over the same period was 456 JPY 100mn. R&D went from 37 JPY 100mn in FY2016 to 67 JPY 100mn in FY2025. Meanwhile revenue of the three segments grew from 472 to 621 JPY 100mn, but operating profit fell from 92 to 45 JPY 100mn — 6 of 9 years were lower than the year before. A structure in which the extra revenue cannot cover the extra depreciation and costs persists for a long time. R&D is not disclosed by segment, so the company-wide total is shown alongside. Large investments in the last 2 years may not be operating yet.スペシャリティ3セグメント(接着材料・高機能材料・ポリマー・オリゴマー)にFY2016~FY2025の間に設備投資717億円(減価償却費311億円)が投じられ、 全社の研究開発費は同期間に456億円だ。研究開発費はFY2016の37億円からFY2025には67億円になった。 その間に3セグメントの売上高は472億円から621億円に増えたが、営業利益は92億円から45億円に減った — 9年中6年が前年を下回った。増えた売上高が増えた減価償却費・費用を賄えない構造が長く続く。 研究開発費はセグメント別に開示されないため、全社合計を併記した。直近2年の大規模投資はまだ稼働前かもしれない。

스페셜티 3부문 설비투자 · 전사 연구개발비 · 억엔Capex in the three specialty segments · company-wide R&D · JPY 100mnスペシャリティ3セグメントの設備投資 · 全社研究開発費 · 億円 · Data as of 2026-09-30 · Created 2026-11-01
스페셜티 3부문 영업이익 · 억엔Operating profit of the three specialty segments · JPY 100mnスペシャリティ3セグメントの営業利益 · 億円 · Data as of 2026-09-30 · Created 2026-11-01
FY매출(억엔)Revenue (JPY 100mn)売上高(億円)영업이익(억엔)Operating profit (JPY 100mn)営業利益(億円)이익률Margin利益率설비투자Capex設備投資감가상각Depreciation減価償却費부문 자산Segment assetsセグメント資産전사 연구개발Company-wide R&D全社研究開発
2016 472 92 19.6% 25 17 400 37
2017 498 95 19.1% 39 18 428 38
2018 510 81 15.9% 53 20 468 37
2019 498 70 14.0% 83 25 542 37
2020 474 66 13.9% 65 29 569 40
2021 578 86 14.8% 49 36 623 44
2022 593 64 10.7% 34 39 669 47
2023 582 51 8.7% 73 40 716 50
2024 607 55 9.0% 121 41 788 58
2025 621 45 7.3% 175 46 959 67
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 연구개발비는 부문별 공시가 없어 전사 합계 · 최근 투자분은 아직 가동 전일 수 있다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: R&D is the company-wide total because it is not disclosed by segment · recent investments may not be operating yet.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 研究開発費はセグメント別の開示がないため全社合計 · 直近の投資分はまだ稼働前の可能性がある。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑨ 기간화학품이 버틴 이유의 절반은 감가상각이 줄어서다⑨ Half the reason commodity chemicals held up is lower depreciation⑨ 基幹化学品が持ちこたえた理由の半分は減価償却費の減少だ

Data as of 2026-09-30 · Created 2026-11-01

기간화학품 영업이익률은 FY2016 7.3%에서 FY2025 11.7%로 4.4%p 올랐다. 나누면 감가상각 전 이익률(현금 마진) 개선이 2.0%p, 매출 대비 감가상각 하락이 2.4%p다. FY2016~FY2021 설비투자는 217억엔으로 감가상각 268억엔에도 못 미쳤다 — 설비를 덜 갱신하며 버틴 구간이다. 감가상각은 2022년에 한 번 꺾였다(FY2021 44억엔 → 구분 변경 전 기준 FY2022 35.3억엔, 변경 후 33.3억엔). 그해 설비투자 170억엔으로 자산이 커졌지만 상각은 아직 거의 잡히지 않았다. 감가상각 방법은 FY2016~FY2025 有報 전부 정액법(定額法), 주요 내용연수(건물 2~75년·기계장치 2~17년) 동일 — 회계 변경 문구 없음(원문 확인 2026-10-19). 수선비는 부문별로 공시되지 않아 보수비 절감 여부는 확인할 수 없다.The commodity chemicals operating margin rose 4.4pp, from 7.3% in FY2016 to 11.7% in FY2025. Broken down, the improvement in the pre-depreciation margin (cash margin) is 2.0pp and the fall in depreciation relative to revenue is 2.4pp. Capex over FY2016~FY2021 was 217 JPY 100mn, short even of depreciation of 268 JPY 100mn — a stretch in which it held up by renewing plant less. Depreciation turned down once in 2022 (FY2021 44 JPY 100mn → FY2022 35.3 JPY 100mn on the pre-reclassification basis, 33.3 JPY 100mn after). Capex of 170 JPY 100mn that year enlarged the asset base, but almost none of it shows up in depreciation yet. 감가상각 방법은 FY2016~FY2025 有報 전부 정액법(定額法), 주요 내용연수(건물 2~75년·기계장치 2~17년) 동일 — 회계 변경 문구 없음(원문 확인 2026-10-19). Repair costs are not disclosed by segment, so whether maintenance spending was cut cannot be confirmed.基幹化学品の営業利益率はFY2016の7.3%からFY2025の11.7%へ4.4%pt上がった。 分解すると、減価償却前利益率(キャッシュマージン)の改善が2.0%pt、売上高に対する減価償却費の低下が2.4%ptだ。 FY2016~FY2021の設備投資は217億円で、減価償却費268億円にも届かなかった — 設備の更新を抑えて持ちこたえた区間だ。 減価償却費は2022年に一度下がった(FY2021 44億円 → 区分変更前ベースのFY2022 35.3億円、 変更後33.3億円)。その年の設備投資170億円で資産は大きくなったが、償却はまだほとんど計上されていない。 감가상각 방법은 FY2016~FY2025 有報 전부 정액법(定額法), 주요 내용연수(건물 2~75년·기계장치 2~17년) 동일 — 회계 변경 문구 없음(원문 확인 2026-10-19)。修繕費はセグメント別に開示されないため、保守費の削減の有無は確認できない。

기간화학품 영업이익률 · 감가상각 전 이익률 · 매출 대비 감가상각 · %Commodity chemicals: operating margin · pre-depreciation margin · depreciation/revenue · %基幹化学品の営業利益率 · 減価償却前利益率 · 売上高比の減価償却費 · % · Data as of 2026-09-30 · Created 2026-11-01
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 2022년 구분 변경 전후의 감가상각은 두 기준이 다르다(본문에 둘 다 적음) · 수선비는 부문 공시가 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Depreciation before and after the 2022 reclassification is on two different bases (both are given in the text) · repair costs are not disclosed by segment.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 2022年の区分変更の前後で減価償却費は2つの基準が異なる(本文に両方を記載)· 修繕費はセグメント別の開示がない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

공통 재무 점검 — 모든 일본 종목에 같은 틀(⑩~)Common financial check — the same frame for every Japanese stock (⑩~)共通の財務点検 — すべての日本株に同じ枠組み(⑩~)

⑩ 손익 패널Income statement panel損益パネル — FY2015~FY2025

억엔 · 비율 = 매출 대비 % · FY = 12월 결산 회계연도(1~12월). 第104期 = FY2016 … 第113期 = FY2025, 第114期 = FY2026.JPY 100mn · ratios = % of revenue · FY = 12월 결산 회계연도(1~12월). 第104期 = FY2016 … 第113期 = FY2025, 第114期 = FY2026.億円 · 比率 = 売上高比% · FY = 12월 결산 회계연도(1~12월). 第104期 = FY2016 … 第113期 = FY2025, 第114期 = FY2026. · Data as of 2026-08-07 · Created 2026-11-01
FY매출Revenue売上高매출총이익률Gross margin売上総利益率판관비율SG&A ratio販管費率연구개발/매출R&D/revenue研究開発費/売上高영업이익Operating profit営業利益영업이익률Operating margin営業利益率경상이익Ordinary profit経常利益특별손익Extraordinary items特別損益순이익Net profit純利益특별 제외 순이익Net profit ex. extraordinary items特別損益除く純利益ROE
20151,39825.3%16.5% 2.7%1238.8%132 -1367 754.2%
20161,35429.3%17.4% 2.7%16111.9%169 38138 1128.5%
20171,44729.4%17.4% 2.6%17512.1%185 2129 1287.4%
20181,50128.1%17.2% 2.5%16410.9%174 1127 1276.9%
20191,45028.1%18.6% 2.6%1389.5%152 1104 1035.5%
20201,33428.5%19.3% 3.0%1239.3%131 -881 874.2%
20211,56329.0%17.7% 2.8%17711.3%190 -2138 1397.0%
20221,60826.7%17.8% 2.9%1448.9%164 9125 1196.1%
20231,59426.0%18.1% 3.2%1257.8%145 26122 1035.8%
20241,67627.3%18.8% 3.5%1428.5%160 6119 1155.6%
20251,62329.0%20.3% 4.1%1428.7%151 23128 1116.0%
반기Half半期매출Revenue売上高매출총이익률Gross margin売上総利益率판관비SG&A販管費영업이익Operating profit営業利益영업이익률Operating margin営業利益率경상이익Ordinary profit経常利益순이익Net profit純利益
2024 H2860 26.7% 16169 8.0% 7248
2025 H1803 28.6% 16070 8.7% 7557
2025 H2820 29.5% 17072 8.7% 7671
2026 H1824 30.7% 17479 9.6% 8660
매출은 FY2015 1,398억엔에서 FY2025 1,623억엔(연 1.5%), 영업이익률은 8.8% → 8.7%. 특별 제외 순이익 = 순이익 − 특별손익 × (1 − 그해 실효세율). 2024-04 四半期報告書 폐지로 2024년 하반기부터는 반기만 있다 — 최근 반기 2026 H1 영업이익 79억엔(전년 같은 반기 70억엔).Revenue went from 1,398 JPY 100mn in FY2015 to 1,623 JPY 100mn in FY2025 (1.5% a year); operating margin 8.8% → 8.7%. Net profit ex. extraordinary items = net profit − extraordinary items × (1 − that year's effective tax rate). With quarterly securities reports abolished in April 2024, only half-year figures exist from the second half of 2024 — latest half 2026 H1: operating profit 79 JPY 100mn (same half a year earlier 70 JPY 100mn).売上高はFY2015の1,398億円からFY2025の1,623億円(年率1.5%)、営業利益率は8.8% → 8.7%。 特別損益除く純利益 = 純利益 − 特別損益 ×(1 − その年の実効税率)。2024年4月の四半期報告書廃止により、2024年下期からは半期のみ — 直近の半期2026 H1の営業利益79億円(前年同半期70億円)。

⑪ 비용 구조 — 매출 1엔이 어디로 가나Cost structure — where each yen of revenue goesコスト構造 — 売上1円はどこへ行くか

매출 대비 %% of revenue売上高比% · Data as of 2026-08-07 · Created 2026-11-01
매출원가율 FY2015 74.7% → FY2025 71.0% · 판관비율 16.5% → 20.3% · 연구개발/매출 2.7% → 4.1% · 감가상각/매출 6.3% → 7.2%. 판매비·일반관리비 구분은 손익계산서 원문 그대로, 연구개발비는 주석의 총액(판관비 안 포함분), 감가상각은 현금흐름표 합계라 다른 선과 겹친다 — 더하면 안 된다.Cost-of-sales ratio FY2015 74.7% → FY2025 71.0% · SG&A ratio 16.5% → 20.3% · R&D/revenue 2.7% → 4.1% · depreciation/revenue 6.3% → 7.2%. The split between selling expenses and general and administrative expenses follows the original income statement; R&D is the total from the notes (including the part within SG&A) and depreciation is the cash-flow-statement total, so they overlap with the other lines — do not add them up.売上原価率FY2015 74.7% → FY2025 71.0% · 販管費率16.5% → 20.3% · 研究開発費/売上高2.7% → 4.1% · 減価償却費/売上高6.3% → 7.2%。 販売費・一般管理費の区分は損益計算書の原文どおり、研究開発費は注記の総額(販管費に含まれる分を含む)、減価償却費はキャッシュ・フロー計算書の合計のため、他の線と重複する — 足し合わせてはならない。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 판관비 구분·연구개발비·감가상각은 원문 계정 그대로라 서로 겹친다(연구개발비는 판관비·제조원가 안에, 감가상각은 현금흐름표 합계) — 더하면 안 된다. 세로축은 로그 눈금.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: The SG&A breakdown, R&D and depreciation follow the original accounts and overlap (R&D sits inside SG&A and manufacturing cost; depreciation is the cash-flow-statement total) — do not add them up. The vertical axis is on a log scale.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 販管費の内訳・研究開発費・減価償却費は原文の勘定科目のままで互いに重複する(研究開発費は販管費・製造原価の中、減価償却費はキャッシュ・フロー計算書の合計)— 足し合わせてはならない。縦軸は対数目盛。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑫ 손익 엔진 — 고정비가 얼마나 무거워졌나Profit engine — how much heavier fixed costs have become損益エンジン — 固定費はどれだけ重くなったか

억엔 · % · 계정 분류(勘定科目法)JPY 100mn · % · account-classification method億円 · % · 勘定科目法 · Data as of 2026-08-07 · Created 2026-11-01
안전마진 — 매출이 몇 % 빠지면 영업적자인가Margin of safety — how far revenue can fall (%) before an operating loss安全余裕率 — 売上が何%減ると営業赤字か
FY201527.9%
FY202524.1%
손익분기 매출 1,009 → 1,232억엔Break-even revenue 1,009 → 1,232 JPY 100mn損益分岐点売上高1,009 → 1,232億円
고정비(판관비 + 감가상각)Fixed costs (SG&A + depreciation)固定費(販管費 + 減価償却費)
FY2015319억엔319 JPY 100mn319億円
FY2025446억엔446 JPY 100mn446億円
공헌이익률 31.7% → 36.2%Contribution margin 31.7% → 36.2%限界利益率31.7% → 36.2%
영업 레버리지 — 매출 1% 변화 → 영업이익 몇 %Operating leverage — % change in operating profit per 1% change in revenue営業レバレッジ — 売上1%の変化 → 営業利益は何%
FY20153.59배3.59x3.59倍
FY20254.15배4.15x4.15倍
공헌이익 ÷ 영업이익Contribution ÷ operating profit限界利益 ÷ 営業利益
변동비율 여유 — 원가율이 몇 %p 오르면 적자인가Variable-cost headroom — how many pp the cost ratio can rise before a loss変動費率の余裕 — 原価率が何%pt上がると赤字か
FY20258.7%p8.7pp8.7%pt
= 영업이익률. 원료가가 판가보다 이만큼 더 오르면 고정비를 못 덮는다.= operating margin. If raw-material prices rise this much more than selling prices, fixed costs are no longer covered.= 営業利益率。原料価格が販売価格よりこれだけ多く上がると、固定費を賄えない。
FY매출Revenue売上高변동비Variable costs変動費고정비Fixed costs固定費공헌이익률Contribution margin限界利益率손익분기 매출Break-even revenue損益分岐点売上高안전마진Margin of safety安全余裕率영업 레버리지Operating leverage営業レバレッジ
20151,398956319 31.7%1,00927.9%3.59
20161,354878315 35.2%89533.9%2.95
20171,447942331 34.9%94734.5%2.90
20181,501995342 33.7%1,01432.5%3.08
20191,450950362 34.5%1,05027.6%3.63
20201,334855356 35.9%99025.8%3.88
20211,5631,004383 35.8%1,06931.6%3.17
20221,6081,074390 33.2%1,17526.9%3.71
20231,5941,073395 32.6%1,21124.0%4.16
20241,6761,106428 34.0%1,25825.0%4.01
20251,6231,035446 36.2%1,23224.1%4.15
회귀로는 못 잰다Not measurable by regression回帰では測れない 분기 비용(매출 − 영업이익)을 매출에 회귀하면 기울기 0.97(±0.04, R² 0.94, 2015Q4~2024Q2 35분기) · 절편(분기 고정비) -26억엔. 비용이 매출과 거의 1:1 로 움직여(판가가 원료에 연동) 고정비가 통계적으로 잡히지 않는다 — 그래서 계정 분류로 나눴다.Regressing quarterly costs (revenue − operating profit) on revenue gives a slope of 0.97 (±0.04, R² 0.94, 2015Q4~2024Q2, 35 quarters) · intercept (quarterly fixed costs) -26 JPY 100mn. Costs move almost 1:1 with revenue (selling prices are linked to raw materials), so fixed costs cannot be identified statistically — hence the split by account.四半期コスト(売上高 − 営業利益)を売上高に回帰すると傾き0.97(±0.04、R² 0.94、2015Q4~2024Q2、35四半期)· 切片(四半期の固定費)-26億円。 コストが売上高とほぼ1:1で動く(販売価格が原料に連動)ため、固定費が統計的に捉えられない — そこで勘定科目で分けた。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 고정비·변동비는 계정으로 나눈 근사이지 회사가 공시한 원가 구조가 아니다 — 매출원가 안 인건비는 변동으로, 판관비 안 운임은 고정으로 들어간다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Fixed and variable costs are an approximation split by account, not a cost structure disclosed by the company — labour costs within cost of sales count as variable and freight within SG&A as fixed.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 固定費・変動費は勘定科目で分けた近似であり、会社が開示した原価構造ではない — 売上原価中の人件費は変動費に、販管費中の運賃は固定費に入る。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑬ 발생액 — 순이익 vs 영업현금흐름Accruals — net profit vs operating cash flow発生高 — 純利益 vs 営業キャッシュ・フロー

억엔JPY 100mn億円 · Data as of 2026-08-07 · Created 2026-11-01
발생액/총자산 3년 평균Accruals/total assets, 3-year average発生高/総資産 3年平均-3.3%
순이익 > 영업현금흐름인 해Years with net profit > operating cash flow純利益 > 営業キャッシュ・フローの年1 / 11년1 / 11 years1 / 11年
누적 영업현금흐름Cumulative operating cash flow累計営業キャッシュ・フロー2,159억엔2,159 JPY 100mn2,159億円
누적 순이익Cumulative net profit累計純利益1,278억엔1,278 JPY 100mn1,278億円
발생액 = 순이익 − 영업현금흐름. 음수면 현금이 이익보다 많이 들어왔다(감가상각이 큰 장치산업의 정상 모습). 크게 양수로 돌면 이익의 질을 의심한다.Accruals = net profit − operating cash flow. A negative value means more cash came in than profit (normal for capital-intensive industries with heavy depreciation). A large swing to positive casts doubt on earnings quality.発生高 = 純利益 − 営業キャッシュ・フロー。マイナスなら利益より多くの現金が入った(減価償却の大きい装置産業では正常な姿)。大きくプラスに転じたら利益の質を疑う。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 연결 연간 값. 영업현금흐름엔 운전자본 변동이 들어 있어 원료 시차가 큰 해에 크게 흔들린다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Consolidated annual figures. Operating cash flow includes working-capital changes, so it swings widely in years with large raw-material time lags.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 連結の年次値。営業キャッシュ・フローには運転資本の増減が含まれるため、原料のタイムラグが大きい年は大きく振れる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑭ CAPEX · FCF — 번 돈과 넣은 돈Capex · FCF — money earned and money investedCAPEX · FCF — 稼いだお金と投じたお金

억엔JPY 100mn億円 · Data as of 2026-08-07 · Created 2026-11-01
누적 설비투자 ÷ 누적 감가상각Cumulative capex ÷ cumulative depreciation累計設備投資 ÷ 累計減価償却費1.46배1.46x1.46倍
최근 3년 설비투자 ÷ 감가상각Capex ÷ depreciation, last 3 years直近3年の設備投資 ÷ 減価償却費1.94배1.94x1.94倍
누적 FCFCumulative FCF累計FCF601억엔601 JPY 100mn601億円
FCF 적자 연도Years with negative FCFFCFマイナスの年2022 · 2024 · 2025
FCF 수익률 FY2025FCF yield FY2025FCF利回り FY2025-5.2%
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 설비투자는 유·무형자산 취득 현금만 — 리스로 들인 자산과 기업 인수는 빠진다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Capex covers only cash paid to acquire property, plant and equipment and intangible assets — leased assets and acquisitions are excluded.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 設備投資は有形・無形固定資産の取得による支出のみ — リースで取得した資産と企業買収は含まない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑮ 운전자본 — 매출채권 · 재고 · 매입채무 회전Working capital — receivables · inventory · payables turnover運転資本 — 売上債権・棚卸資産・仕入債務の回転

일 · 기말 잔액 기준Days · year-end balances日 · 期末残高ベース · Data as of 2026-08-07 · Created 2026-11-01
현금 전환 주기(CCC = DSO + DIO − DPO)는 FY2015 111일 → FY2025 140일 (매출채권 101 → 111일 · 재고 56 → 81일 · 매입채무 46 → 52일). 늘어난 29일을 FY2025 매출로 환산하면 약 127억엔이 운전자본에 더 묶여 있다. 매출채권은 전자기록채권 포함. 재고는 매출원가 기준.The cash conversion cycle (CCC = DSO + DIO − DPO) went from 111 days in FY2015 to 140 days in FY2025 (receivables 101 → 111 days · inventory 56 → 81 days · payables 46 → 52 days). Converting the 29 additional days at FY2025 revenue, about 127 JPY 100mn more is tied up in working capital. Receivables include electronically recorded monetary claims. Inventory is measured against cost of sales.キャッシュ・コンバージョン・サイクル(CCC = DSO + DIO − DPO)はFY2015の111日 → FY2025の140日 (売上債権101 → 111日 · 棚卸資産56 → 81日 · 仕入債務46 → 52日)。 増えた29日をFY2025の売上高で換算すると、約127億円が運転資本に余分に拘束されている。 売上債権は電子記録債権を含む。棚卸資産は売上原価ベース。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 기말 잔액 기준이라 결산일 계절성이 섞인다. 매출채권은 전자기록채권을 포함(공시된 해)하고, 재고·매입채무는 매출원가 기준.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Based on year-end balances, so balance-sheet-date seasonality is mixed in. Receivables include electronically recorded monetary claims (in years they are disclosed); inventories and payables are measured against cost of sales.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 期末残高ベースのため決算日の季節性が混じる。売上債権は電子記録債権を含み(開示された年)、棚卸資産・仕入債務は売上原価ベース。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑯ ROIC · ROE · ROA — 자본에서 얼마를 버나ROIC · ROE · ROA — how much is earned on capitalROIC・ROE・ROA — 資本からどれだけ稼ぐか

% · Data as of 2026-08-07 · Created 2026-11-01
ROIC(세후 영업이익 ÷ 영업 투하자본)는 FY2015 8.5% · 고점 FY2017 15.1% · FY2025 6.6%. 영업 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유주식 포함) — 본업에 묶인 돈만 남긴다. ROE·ROA 는 기초·기말 평균 분모.ROIC (after-tax operating profit ÷ operating invested capital) was 8.5% in FY2015 · peak FY2017 15.1% · FY2025 6.6%. Operating invested capital = equity + interest-bearing debt − cash and short-term securities − investment securities (including cross-shareholdings) — leaving only the money tied up in the core business. ROE and ROA use the average of opening and closing balances as the denominator.ROIC(税引後営業利益 ÷ 営業投下資本)はFY2015 8.5% · ピークFY2017 15.1% · FY2025 6.6%。 営業投下資本 = 自己資本 + 有利子負債 − 現金・短期有価証券 − 投資有価証券(政策保有株式を含む)— 本業に拘束されたお金だけを残す。ROE・ROAは期首・期末の平均を分母とする。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 영업 투하자본에서 투자유가증권(정책보유 포함)을 뺐다 · 세율은 그해 실효세율 · 기초·기말 평균 분모라 첫 해는 기말만.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Investment securities (including cross-shareholdings) are excluded from operating invested capital · the tax rate is that year's effective rate · denominators average opening and closing balances, so the first year uses the closing balance only.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 営業投下資本から投資有価証券(政策保有株式を含む)を除いた · 税率はその年の実効税率 · 分母は期首・期末の平均のため、初年度は期末のみ。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑰ 자본 배분 — FY2015~FY2025 누적, 돈은 어디로 갔나Capital allocation — cumulative FY2015~FY2025: where did the money go資本配分 — FY2015~FY2025累計、お金はどこへ行ったか

억엔 · 현금흐름표 누계JPY 100mn · cumulative cash-flow statement億円 · キャッシュ・フロー計算書の累計 · Data as of 2026-08-07 · Created 2026-11-01
영업현금흐름Operating cash flow営業キャッシュ・フロー2,159억엔2,159 JPY 100mn2,159億円
설비투자Capex設備投資1,558억엔1,558 JPY 100mn1,558億円
주주환원(배당 + 자사주)Shareholder returns (dividends + buybacks)株主還元(配当 + 自社株買い)809억엔809 JPY 100mn809億円
투자주식 매각 대금Proceeds from selling investment securities投資有価証券の売却収入266억엔266 JPY 100mn266億円
순현금 변화(기말 − 기초)Change in net cash (closing − opening)ネットキャッシュの増減(期末 − 期首)-344억엔-344 JPY 100mn-344億円
FCF 601억엔 vs 주주환원 809억엔 — 환원이 FCF 를 넘었다. 차액은 투자주식 매각과 순현금 감소로 메웠다. 누적은 첫 해 포함. 순현금 변화 = 마지막 해 − 첫 해 기말.FCF 601 JPY 100mn vs shareholder returns 809 JPY 100mn — returns exceeded FCF; the gap was covered by selling investment securities and drawing down net cash. 누적은 첫 해 포함. 순현금 변화 = 마지막 해 − 첫 해 기말.FCF 601億円 vs 株主還元809億円 — 還元がFCFを上回った。差額は投資有価証券の売却とネットキャッシュの減少で賄った。 누적은 첫 해 포함. 순현금 변화 = 마지막 해 − 첫 해 기말.
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 현금흐름표 누계 — 연결 범위 변경·환율 효과·기타 재무 항목은 따로 싣지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Cumulative cash-flow-statement figures — changes in the scope of consolidation, FX effects and other financing items are not shown separately.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: キャッシュ・フロー計算書の累計 — 連結範囲の変更・為替の影響・その他の財務項目は個別に載せていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑱ 특별손익 — 본업 밖 이익이 얼마나 받치나Extraordinary items — how much non-core profit props up earnings特別損益 — 本業以外の利益がどれだけ支えているか

억엔JPY 100mn億円 · Data as of 2026-08-07 · Created 2026-11-01
FY특별이익Extraordinary gains特別利益투자주식 매각익Gains on sale of investment securities投資有価証券売却益특별손실Extraordinary losses特別損失감손Impairment減損특별손익 ÷ 세전이익Extraordinary items ÷ pre-tax profit特別損益 ÷ 税引前利益
20158.30.421.7 18.3-11.3%
201643.26.25.5 0.218.2%
20178.54.56.5 2.11.1%
20183.30.02.5 —0.5%
20195.75.55.1 4.10.4%
20202.52.510.5 1.8-6.5%
202118.417.120.2 10.3-1.0%
202228.425.519.7 9.65.0%
202341.640.815.7 —15.2%
202444.243.338.6 14.93.4%
202553.352.630.5 4.013.1%
FY2015~FY2025 투자주식 매각익 누계 198억엔 = 누적 순이익 1,278억엔의 15.5%(세전 기준이라 상한). 최근 3년 특별손익 ÷ 세전이익 평균 10.6%.Cumulative gains on sale of investment securities FY2015~FY2025: 198 JPY 100mn = 15.5% of cumulative net profit of 1,278 JPY 100mn (pre-tax basis, so an upper bound). Average extraordinary items ÷ pre-tax profit over the last 3 years: 10.6%.FY2015~FY2025の投資有価証券売却益の累計198億円 = 累計純利益1,278億円の15.5%(税引前ベースのため上限)。直近3年の特別損益 ÷ 税引前利益の平均10.6%。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 특별손익은 일본기준 손익계산서 구분 그대로 · 특별 제외 순이익은 그해 실효세율로 세후 환산한 근사.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Extraordinary items follow the Japan GAAP income-statement classification · net profit excluding extraordinary items is an approximation converted to after-tax at that year's effective tax rate.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 特別損益は日本基準の損益計算書の区分のまま · 特別損益除く純利益はその年の実効税率で税引後に換算した近似。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑲ 4분기 편중 — 비용을 연말에 몰았나Q4 concentration — were costs bunched at year-end?第4四半期への偏り — 費用を期末に寄せたか

연간 대비 4분기 비중 · 분기 공시 기간 FY2016~FY2023Q4 share of the full year · quarterly-disclosure period FY2016~FY2023通期に対する第4四半期の比重 · 四半期開示期間FY2016~FY2023 · Data as of 2026-08-07 · Created 2026-11-01
균등선 = 한 해의 4분의 1. 판관비 4분기 비중 최대 27.1%. 영업이익 비중이 크게 흔들리는 해는 매출·판관비가 아니라 원가(원료 시차)에서 왔다 — 4분기 영업이익률과 1~3분기 영업이익률 차이로 본다. 2024-04 이후는 반기만 있어 이 점검이 끊긴다.Even line = one quarter of the year. Maximum Q4 share of SG&A: 27.1%. Years in which the operating-profit share swings widely stem from cost of sales (raw-material time lags), not from revenue or SG&A — judged from the gap between the Q4 operating margin and the Q1–Q3 operating margin. From April 2024 there are only half-year figures, so this check stops.均等線 = 1年の4分の1。販管費の第4四半期比重の最大27.1%。営業利益の比重が大きく振れる年は、売上高・販管費ではなく原価(原料のタイムラグ)から来た — 第4四半期の営業利益率と第1~3四半期の営業利益率の差で見る。2024年4月以降は半期のみのため、この点検は途切れる。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 분기보고서가 있던 기간만 — 2024년 하반기부터는 반기라 이 점검이 끊긴다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Only the period when quarterly reports existed — from the second half of 2024 there are only half-year figures, so this check stops.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 四半期報告書があった期間のみ — 2024年下期からは半期のため、この点検は途切れる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

⑳ 장부 점검 게이지 — 6개 플래그Accounting check gauges — 6 flags帳簿点検ゲージ — 6個のフラグ

빨강 0 · 주황 4 · 최근 연도 기준Red 0 · amber 4 · latest year赤0 · 橙4 · 直近年度ベース · Data as of 2026-08-07 · Created 2026-11-01
이익−현금 괴리(발생액/총자산, 3년 평균)Profit–cash gap (accruals/total assets, 3-year average)利益と現金の乖離(発生高/総資産、3年平均)
-3.3%-3.3%-3.3% · 기준 5%· threshold 5%· 基準5%
순이익이 영업현금흐름보다 크게 앞서면 이익의 질을 의심한다(Sloan).순이익이 영업현금흐름보다 크게 앞서면 이익의 질을 의심한다(Sloan).순이익이 영업현금흐름보다 크게 앞서면 이익의 질을 의심한다(Sloan).
매출채권 증가 − 매출 증가(최근 연도)Receivables growth − revenue growth (latest year)売上債権の増加 − 売上高の増加(直近年度)
-1.9%-1.9%-1.9% · 기준 10%· threshold 10%· 基準10%
채권이 매출보다 빨리 늘면 밀어내기·회수 지연 신호.채권이 매출보다 빨리 늘면 밀어내기·회수 지연 신호.채권이 매출보다 빨리 늘면 밀어내기·회수 지연 신호.
재고 증가 − 매출 증가(최근 연도)Inventory growth − revenue growth (latest year)棚卸資産の増加 − 売上高の増加(直近年度)
6.1%6.1%6.1% · 기준 10%· threshold 10%· 基準10%
재고가 매출보다 빨리 늘면 수요 둔화를 재고로 받고 있을 수 있다(원가 이연).재고가 매출보다 빨리 늘면 수요 둔화를 재고로 받고 있을 수 있다(원가 이연).재고가 매출보다 빨리 늘면 수요 둔화를 재고로 받고 있을 수 있다(원가 이연).
특별손익 ÷ 세전이익(3년 평균)Extraordinary items ÷ pre-tax profit (3-year average)特別損益 ÷ 税引前利益(3年平均)
10.6%10.6%10.6% · 기준 20%· threshold 20%· 基準20%
투자주식 매각익 등 본업 밖 이익이 세전이익을 받치고 있는지.투자주식 매각익 등 본업 밖 이익이 세전이익을 받치고 있는지.투자주식 매각익 등 본업 밖 이익이 세전이익을 받치고 있는지.
설비투자 ÷ 감가상각(3년) vs 매출 연성장Capex ÷ depreciation (3 years) vs annual revenue growth設備投資 ÷ 減価償却費(3年)vs 売上高の年成長率
1.94배1.94x1.94倍 · 기준 2.0배· threshold 2.0x· 基準2.0倍
상각의 2배 넘게 투자하는데 매출 3년 연성장이 3% 미만이면 투자 회수가 의문. 매출 3년 연성장 0.3%.상각의 2배 넘게 투자하는데 매출 3년 연성장이 3% 미만이면 투자 회수가 의문. 매출 3년 연성장 0.3%.상각의 2배 넘게 투자하는데 매출 3년 연성장이 3% 미만이면 투자 회수가 의문. 매출 3년 연성장 0.3%.
4분기 판관비 몰림(최대 연도 · 분기 공시 기간)Q4 bunching of SG&A (peak year · quarterly-disclosure period)第4四半期への販管費の集中(最大の年 · 四半期開示期間)
27.1%27.1%27.1% · 기준 30%· threshold 30%· 基準30%
한 해 판관비의 25%가 균등. 4분기에 비용을 몰아 앞 분기 이익을 부풀렸는지 — 최대 FY2021. 2024-04 분기보고서 폐지로 이후는 못 본다.한 해 판관비의 25%가 균등. 4분기에 비용을 몰아 앞 분기 이익을 부풀렸는지 — 최대 FY2021. 2024-04 분기보고서 폐지로 이후는 못 본다.한 해 판관비의 25%가 균등. 4분기에 비용을 몰아 앞 분기 이익을 부풀렸는지 — 최대 FY2021. 2024-04 분기보고서 폐지로 이후는 못 본다.

㉑ 밸류에이션 — P/B · P/E · EV/EBITDAValuation — P/B · P/E · EV/EBITDAバリュエーション — P/B・P/E・EV/EBITDA

배 · 기말 주가는 가공값x · year-end prices are derived values倍 · 期末株価は加工値 · Data as of 2026-08-07 · Created 2026-11-01
FY시가총액(억엔)Market cap (JPY 100mn)時価総額(億円)P/BP/EEV/EBITDA배당수익률Dividend yield配当利回りFCF 수익률FCF yieldFCF利回り순현금 ÷ 시총Net cash ÷ market capネットキャッシュ ÷ 時価総額투자유가증권 ÷ 시총Investment securities ÷ market cap投資有価証券 ÷ 時価総額
20151,3730.8720.5 4.42.30%13.6% 32.1%19.9%
20161,5180.9011.0 3.82.25%10.3% 39.9%17.8%
20171,8851.0314.6 4.91.82%4.7% 34.1%18.7%
20181,5940.8512.5 3.72.31%5.1% 41.9%17.4%
20191,6720.8616.1 4.42.36%2.0% 38.9%17.2%
20201,5520.8019.4 4.22.48%4.0% 39.8%17.3%
20211,4470.7210.7 2.93.11%6.7% 44.2%19.9%
20221,3500.6611.0 3.63.23%-6.9% 34.1%21.1%
20231,5920.7513.3 5.03.88%6.3% 27.5%20.7%
20241,6990.8014.5 5.53.96%-1.1% 17.4%20.0%
20251,7580.8214.0 6.43.97%-5.2% 5.5%20.5%
시가총액 = 기말 주가(가공) × (발행주식 − 자기주식). EV = 시가총액 + 이자부채(리스 포함) − 현금·단기유가증권. 투자유가증권(정책보유 포함)은 EV 에서 빼지 않았다 — 표의 마지막 열이 그 크기다.Market cap = year-end price (derived) × (shares issued − treasury shares). EV = market cap + interest-bearing debt (including leases) − cash and short-term securities. Investment securities (including cross-shareholdings) are not deducted from EV — the last column of the table shows their size.時価総額 = 期末株価(加工値)×(発行済株式数 − 自己株式数)。EV = 時価総額 + 有利子負債(リースを含む)− 現金・短期有価証券。投資有価証券(政策保有株式を含む)はEVから差し引いていない — 表の最終列がその大きさだ。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 기말 주가는 그해 有報의 EPS × PER 로 역산한 가공값 — 시장 주가 원천을 쓰지 않았다. 적자 해는 PER 미기재로 빈칸.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Year-end share prices are derived values back-calculated as EPS × P/E from that year's annual securities report — no market price source is used. Loss years are blank because P/E is not reported.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 期末株価はその年の有報のEPS × PERから逆算した加工値 — 市場の株価データは使っていない。赤字の年はPER記載なしのため空欄。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

㉒ P/E 냐 P/B 냐 — 이 주가는 무엇을 따라가나P/E or P/B — what does this share price track?P/EかP/Bか — この株価は何に連動するか

有報 5년 표 FY2012~FY20255-year tables in the annual securities reports FY2012~FY2025有報の5年表 FY2012~FY2025 · Data as of 2026-08-07 · Created 2026-11-01
이 종목 · 그해 이익 기준This stock · same-year earningsこの銘柄 · その年の利益ベース
β 0.02
log(P/B) 를 log(ROE) 에 회귀한 기울기(±0.17, 14년). 1 이면 ROE 가 변해도 P/E 가 그대로(이익을 따라감), 0 이면 P/B 가 그대로(장부에 묶임). → P/B 에 묶여 있다.Slope from regressing log(P/B) on log(ROE) (±0.17, 14 years). 1 means P/E stays put as ROE changes (tracks earnings); 0 means P/B stays put (anchored to book). → anchored to P/B.log(P/B)をlog(ROE)に回帰した傾き(±0.17、14年)。1ならROEが変わってもP/Eは不変(利益に連動)、0ならP/Bが不変(簿価に縛られる)。→ P/Bに縛られている。
이 종목 · 3년 평균 이익 기준This stock · 3-year average earningsこの銘柄 · 3年平均利益ベース
β 0.57
일시 이익은 주가에 안 실린다(일회성이면 P/E 가 반대로 움직인다). 3년 평균 EPS 로 바꿔 다시 잰 값(±0.34, 12년) → 평탄화 이익(3년 평균)으로 보면 둘 사이.One-off profits are not priced in (if a profit is one-off, P/E moves the other way). Re-measured with 3-year average EPS (±0.34, 12 years) → in between on smoothed earnings (3-year average).一時的な利益は株価に織り込まれない(一過性ならP/Eが逆に動く)。3年平均EPSに替えて測り直した値(±0.34、12年) → 平準化利益(3年平均)で見ると両者の中間。
P/B 변화 분해 FY2012→FY2025Decomposition of P/B change FY2012→FY2025P/B変化の分解 FY2012→FY2025
+19%
log(P/B) 변화 = log(ROE) -23% + log(P/E) +42%. P/B 범위 0.66~1.03배 · 표준편차(log) P/E 0.23 vs P/B 0.12.Change in log(P/B) = log(ROE) -23% + log(P/E) +42%. P/B range 0.66~1.03x · standard deviation (log) P/E 0.23 vs P/B 0.12.log(P/B)の変化 = log(ROE) -23% + log(P/E) +42%。P/Bの範囲0.66~1.03倍 · 標準偏差(log)P/E 0.23 vs P/B 0.12。
일본 시장 표본 369사 · 회사 안 시계열Japan market sample, 369 companies · within-company time series日本市場の標本369社 · 企業内の時系列
β 0.15
같은 회귀를 369사(3443개 회사-연도)에 — 3년 평균 이익 기준 β 0.18. 회사별 β 중앙값 0.22. 그해 이익으로도, 3년 평균 이익으로도 β 가 0 쪽 — 일본 주가는 평균적으로 이익보다 장부(P/B)에 묶여 있다.The same regression across 369 companies (3443 company-years) — β on 3-year average earnings 0.18. Median company β 0.22. 그해 이익으로도, 3년 평균 이익으로도 β 가 0 쪽 — 일본 주가는 평균적으로 이익보다 장부(P/B)에 묶여 있다.同じ回帰を369社(3443の企業・年度)に — 3年平均利益ベースのβ 0.18。企業別βの中央値0.22。그해 이익으로도, 3년 평균 이익으로도 β 가 0 쪽 — 일본 주가는 평균적으로 이익보다 장부(P/B)에 묶여 있다.
점 하나 = 한 해(그해 ROE = EPS ÷ BPS, P/B = PER × EPS ÷ BPS — 둘 다 같은 有報 5년 표의 같은 주식 기준이라 분할·병합에 무관). 적자 해는 PER 이 비어 빠진다(0년).Each dot = one year (ROE that year = EPS ÷ BPS, P/B = P/E × EPS ÷ BPS — both on the same share basis from the same 5-year table in the annual securities report, so unaffected by splits and consolidations). Loss years have no P/E and are excluded (0 years).点1つ = 1年(その年のROE = EPS ÷ BPS、P/B = PER × EPS ÷ BPS — どちらも同じ有報5年表の同じ株式ベースのため、分割・併合の影響を受けない)。赤字の年はPERが空欄のため除外(0年)。
出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 한 회사의 연간 관측이라 표본이 작다(표준오차를 함께 적었다) · 적자 해는 빠진다 · 평탄화 이익은 그해 포함 직전 연도들의 EPS/BPS 평균.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: Annual observations of a single company, so the sample is small (standard errors are shown alongside) · loss years are excluded · smoothed earnings are the average EPS/BPS of the preceding years including that year.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)
EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)
Limitations: 1社の年次観測のため標本が小さい(標準誤差を併記した)· 赤字の年は除外 · 平準化利益はその年を含む直近数年のEPS/BPSの平均。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

㉓ 측정 한계Measurement limitations測定の限界

1고정비·변동비는 계정 분류(매출원가 − 감가상각 = 변동, 판관비 + 감가상각 = 고정) 근사다. 매출원가 안 인건비(반고정)는 변동으로, 판관비 안 운임(변동)은 고정으로 들어간다. 감가상각은 현금흐름표 합계라 판관비 몫이 겹친다.고정비·변동비는 계정 분류(매출원가 − 감가상각 = 변동, 판관비 + 감가상각 = 고정) 근사다. 매출원가 안 인건비(반고정)는 변동으로, 판관비 안 운임(변동)은 고정으로 들어간다. 감가상각은 현금흐름표 합계라 판관비 몫이 겹친다.고정비·변동비는 계정 분류(매출원가 − 감가상각 = 변동, 판관비 + 감가상각 = 고정) 근사다. 매출원가 안 인건비(반고정)는 변동으로, 판관비 안 운임(변동)은 고정으로 들어간다. 감가상각은 현금흐름표 합계라 판관비 몫이 겹친다.
22024-04 四半期報告書 폐지 → 2024년 하반기부터는 반기만 있다. 4분기 편중·분기 회귀는 그 전 기간만.2024-04 四半期報告書 폐지 → 2024년 하반기부터는 반기만 있다. 4분기 편중·분기 회귀는 그 전 기간만.2024-04 四半期報告書 폐지 → 2024년 하반기부터는 반기만 있다. 4분기 편중·분기 회귀는 그 전 기간만.
3기말 주가는 有報 5년 표의 PER × EPS 로 역산한 가공값이다. 적자 해(PER 미기재)는 주가·P/B 가 비고, 그해는 P/E·P/B 판정에서 빠진다.기말 주가는 有報 5년 표의 PER × EPS 로 역산한 가공값이다. 적자 해(PER 미기재)는 주가·P/B 가 비고, 그해는 P/E·P/B 판정에서 빠진다.기말 주가는 有報 5년 표의 PER × EPS 로 역산한 가공값이다. 적자 해(PER 미기재)는 주가·P/B 가 비고, 그해는 P/E·P/B 판정에서 빠진다.
4ROIC 의 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유 포함). 세율은 그해 실효세율(0~60% 밖이면 30.6%).ROIC 의 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유 포함). 세율은 그해 실효세율(0~60% 밖이면 30.6%).ROIC 의 투하자본 = 자기자본 + 이자부채 − 현금·단기유가증권 − 투자유가증권(정책보유 포함). 세율은 그해 실효세율(0~60% 밖이면 30.6%).

出典:EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)、PDL1.0(https://www.digital.go.jp/resources/open_data/public_data_license_v1.0)

EDINET閲覧(提出)サイト(https://disclosure2.edinet-fsa.go.jp/)の東亞合成株式会社提出書類をもとにAdrenalin Baby作成(編集・加工)

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).

Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage